Proton Pump Inhibitors: A Balanced View
A Balanced View
1st Edition
Published on 23. September 2013
120 pages
978-3-318-02416-6 (ISBN)
Available for download
Description
The discovery of proton pump inhibitors (PPIs) and their development over the years has dramatically changed the management of acid-related diseases. Today, the therapeutic domain of PPIs ranges from relief of symptoms to cure of mucosal lesions in the upper gastrointestinal tract. PPIs are among the most widely sold drugs in the world and are now even available as over-the-counter medication. This publication presents the experience of the last 25 years during which PPIs have become of enormous value in gastroenterology. The authors provide an update on a variety of subjects, starting with an introduction to the discovery and development of PPIs. This is followed by chapters on pharmacokinetics, pharmacodynamics and pharmacogenetics, gastroesophageal reflux disease, gastroprotection, Helicobacter pylori eradication treatment, peptic ulcer disease, functional dyspepsia, acid suppression in exocrine pancreatic insufficiency, and gastrointestinal and systemic side effects. Readers who are interested in a current overview of PPIs and their various applications will find this book of great value.
More details
Other editions
Additional editions
T. Chiba | P. Malfertheiner | H. Satoh
Proton Pump Inhibitors: A Balanced View
Book
09/2013
1st Edition
S. Karger
€177.60
Article exhausted; check different version
Persons
Content
- Cover
- Front Matter
- Contents
- Preface
- Discovery and Development of Proton Pump Inhibitors
- Abstract
- The Discovery of Proton Pump Inhibitors
- Discovery of 2-Pyridylthioacetamide (AG-35, CMN 131)
- Discovery of Timoprazole (AG-879, H 83/69)
- Introduction of Fluorinated Substituents to Timoprazole
- Antisecretory Mechanism of Proton Pump Inhibitors
- Pharmacological Properties of Lansoprazole Unrelated to Antisecretory Activity
- Effects of Lansoprazole on Small Intestinal Lesions Induced by NSAIDs
- Effect of Lansoprazole on Helicobacter pylori
- Development of Proton Pump Inhibitors
- Long-Term Toxicity Studies
- Development of Orally Disintegrating Lansoprazole Tablets
- Development of an Injectable Formulation of Lansoprazole
- Development of Single Enantiomers of Omeprazole and Lansoprazole (Esomeprazole, Dexlansoprazole)
- Development of a Potassium-Competitive Acid Blocker (TAK-438)
- Comments
- Acknowledgements
- References
- Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Proton Pump Inhibitors
- Abstract
- Effects of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors
- Genotype and Phenotypes of CYP2C19
- Influences of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitors
- Drug-Drug Interaction between Proton Pump Inhibitors and Other Drugs in Relation to CYP2C19 Polymorphisms
- Effects of Proton Pump Inhibitors on the Activity of P450
- Interaction between Proton Pump Inhibitors and Clarithromycin
- Interaction between Proton Pump Inhibitors and Clopidogrel
- Conclusion
- References
- Proton Pump Inhibitors in Gastroesophageal Reflux Disease
- Abstract
- General Evaluation before Treatment of Gastroesophageal Reflux Disease
- Proton Pump Inhibitors in the Treatment of Nonerosive Reflux Disease
- Proton Pump Inhibitors in the Treatment of Erosive Esophagitis
- Proton Pump Inhibitors in Specific Conditions Related to Gastroesophageal Reflux Disease
- Proton Pump Inhibitor Nonresponders: Refractory Gastroesophageal Reflux Disease
- Long-Term Gastroesophageal Reflux Disease Management with Proton Pump Inhibitors
- Conclusions
- References
- Proton Pump Inhibitors in Gastroprotection: Prevention and Healing of Nonsteroidal Anti-Inflammatory Drug-, Aspirin-, and Cyclooxygenase-2 Inhibitor-Induced Gastroduodenal Lesions
- Abstract
- Pathophysiology of Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease
- Proton Pump Inhibitors and Healing of Traditional Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Lesions
- Proton Pump Inhibitors and Prevention of tNSAID-Induced Gastroduodenal Lesions
- Short-Term Treatment with Proton Pump Inhibitors (&3 Months of Nonsteroidal Anti-Inflammatory Drug Exposure)
- Long-Term Treatment with Proton Pump Inhibitors (&3 Months of Nonsteroidal Anti-Inflammatory Drug Exposure)
- Proton Pump Inhibitors and Prevention of Aspirin-Induced Gastroduodenal Lesions
- Proton Pump Inhibitors versus Placebo
- Proton Pump Inhibitors versus H 2 -Receptor Antagonists
- Proton Pump Inhibitors and Prevention of Cyclooxygenase-2 Inhibitor-Induced Gastroduodenal Lesions
- Review and Recommendation Based on Risk Assessment
- References
- Proton Pump Inhibitors: Key Ingredients in Helicobacter pylori Eradication Treatment
- Abstract
- Proton Pump Inhibitors Are Key Ingredients in Eradication Regimens
- How Do Proton Pump Inhibitors Show Antibacterial Effects against H. pylori?
- What Proton Pump Inhibitors Are Desirable in Eradication Treatment?
- What Regimen Is Recommended in the New Era?
- References
- Proton Pump Inhibitor Management in Bleeding Peptic Ulcer Disease
- Abstract
- Why Proton Pump Inhibitors in Bleeding Peptic Disease?
- Do Proton Pump Inhibitors Work in Real-Life Peptic Ulcer Bleeding?
- Would Intermittent Injection of Proton Pump Inhibitors or Low-Dose Proton Pump Inhibitors Work?
- Would High-Dose Oral Proton Pump Inhibitors Work?
- Should Proton Pump Inhibitors Be Given before Endoscopy?
- References
- Proton Pump Inhibitors in Functional Dyspepsia
- Abstract
- Model of Functional Dyspepsia Pathogenesis
- Role of Acid in Functional Dyspepsia Pathophysiology
- Role and Efficacy of Proton Pump Inhibitors as Pharmacotherapeutic Agents for Functional Dyspepsia
- References
- Role of Acid Suppression in Exocrine Pancreatic Insufficiency: A Therapeutic Principle
- Abstract
- Effects of Chronic Pancreatitis on Digestion
- Acid in Chronic Pancreatitis
- Pharmacological Treatment of Exocrine Pancreatic Insufficiency
- The Role of Acid Suppression in Treatment of Exocrine Pancreatic Insufficiency
- Conclusion
- References
- Proton Pump Inhibitors and Gastrointestinal Side Effects
- Abstract
- Rebound Acid Hypersecretion
- Diarrhea and Enteric Bacteria
- Microscopic Colitis (Collagenous Colitis and Lymphocytic Colitis)
- Fundic Gland Polyps
- Development of Enterochromaffin-Like Cell Hyperplasia and Enterochromaffin-Like Carcinoid Tumor: Neuroendocrine Tumor G1
- Progression of Chronic Atrophic Gastritis and Gastric Cancer
- References
- Administration of Proton Pump Inhibitors and Risk of Systemic Side Effects
- Abstract
- Impaired Absorption of Nutrients
- Decreased Calcium Absorption and Bone Fracture
- Impaired Iron Absorption and Iron Deficiency Anemia
- Impaired Vitamin B 12 Absorption
- Decreased Bactericidal Effect of Gastric Acid
- Pneumonia
- Decreased Acid Secretion and Altered Absorption of Coadministered Drugs
- Increased Absorption of Digoxin, Methyldigoxin, Nifedipine, and Alendronate
- Decreased Absorption of Atazanavir, Itraconazole, Ketoconazole, Cefpodoxime, Enoxacin, Gefitinib, Dipyridamole, and Aspirin
- Interaction of Proton Pump Inhibitors at CYP2C19 with Coadministered Drugs
- Clopidogrel
- Warfarin
- Diazepam, Phenytoin, Cilostazol, and Tacrolimus
- Other Possible Important Systemic Side Effects
- Conclusion
- References
- Author Index
- Subject Index
- Cover
